hydromethylthionine has been researched along with Atrophy in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentham, P; Gauthier, S; Kook, K; Miller, S; Schelter, BO; Wischik, CM | 1 |
| Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Harrington, CR; Jia, J; Kook, K; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM | 1 |
| Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Hardlund, J; Harrington, CR; Jia, J; Kipps, CM; Kook, K; Moebius, HJ; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM; Wischik, DJ | 1 |
| Bentham, P; Harrington, CR; Schelter, BO; Shiells, H; Staff, RT; Wischik, CM | 1 |
3 trial(s) available for hydromethylthionine and Atrophy
| Article | Year |
|---|---|
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.
Topics: Activities of Daily Living; Alzheimer Disease; Atrophy; Fluorodeoxyglucose F18; Humans; Mesylates | 2022 |
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Brain; Cognitive Dysfunction; Dose-Response Relationship, Drug; Female; Humans; Male; Methylene Blue | 2019 |
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
Topics: Adult; Aged; Atrophy; Brain; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Frontotemporal Dementia; Humans; Magnetic Resonance Imaging; Male; Methylene Blue; Middle Aged; Treatment Outcome | 2020 |
1 other study(ies) available for hydromethylthionine and Atrophy
| Article | Year |
|---|---|
Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier.
Topics: Adult; Atrophy; Brain; Carrier State; Frontotemporal Dementia; Humans; Magnetic Resonance Imaging; Male; Methylene Blue; Mutation; tau Proteins; Time Factors | 2021 |